| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 13 | 2019 | 563 | 1.100 |
Why?
|
| Neoplasms, Glandular and Epithelial | 6 | 2017 | 67 | 0.760 |
Why?
|
| Solute Carrier Organic Anion Transporter Family Member 1B3 | 6 | 2020 | 16 | 0.680 |
Why?
|
| Vaping | 4 | 2020 | 123 | 0.560 |
Why?
|
| Venous Thromboembolism | 4 | 2022 | 132 | 0.540 |
Why?
|
| Survivors | 1 | 2016 | 36 | 0.530 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2022 | 367 | 0.490 |
Why?
|
| Middle Aged | 27 | 2024 | 6818 | 0.490 |
Why?
|
| Humans | 54 | 2024 | 26829 | 0.480 |
Why?
|
| Neoplasms | 3 | 2022 | 755 | 0.480 |
Why?
|
| Indians, North American | 4 | 2019 | 511 | 0.470 |
Why?
|
| Organic Anion Transporters | 3 | 2020 | 7 | 0.470 |
Why?
|
| Female | 38 | 2024 | 14463 | 0.460 |
Why?
|
| Retrospective Studies | 21 | 2022 | 2433 | 0.450 |
Why?
|
| Aged | 22 | 2024 | 5167 | 0.450 |
Why?
|
| Cation Transport Proteins | 3 | 2019 | 54 | 0.440 |
Why?
|
| Drug Interactions | 6 | 2020 | 77 | 0.440 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2019 | 146 | 0.430 |
Why?
|
| Adult | 24 | 2022 | 7383 | 0.430 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2022 | 277 | 0.420 |
Why?
|
| Polycomb Repressive Complex 1 | 3 | 2018 | 34 | 0.420 |
Why?
|
| Aged, 80 and over | 15 | 2021 | 1927 | 0.370 |
Why?
|
| Antineoplastic Agents | 5 | 2019 | 657 | 0.350 |
Why?
|
| Glaucoma, Open-Angle | 2 | 2022 | 22 | 0.330 |
Why?
|
| Pancreatic Neoplasms | 3 | 2020 | 507 | 0.320 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2022 | 309 | 0.320 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 2 | 2019 | 26 | 0.320 |
Why?
|
| Liver Neoplasms | 2 | 2024 | 164 | 0.310 |
Why?
|
| Cytoreduction Surgical Procedures | 3 | 2017 | 31 | 0.310 |
Why?
|
| Endometrial Neoplasms | 2 | 2022 | 184 | 0.310 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2024 | 276 | 0.300 |
Why?
|
| Carrier Proteins | 2 | 2020 | 245 | 0.290 |
Why?
|
| Adolescent | 14 | 2021 | 2957 | 0.290 |
Why?
|
| Cell Line, Tumor | 10 | 2020 | 1259 | 0.280 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 2 | 2017 | 14 | 0.280 |
Why?
|
| Carcinoma, Endometrioid | 2 | 2017 | 39 | 0.280 |
Why?
|
| MicroRNAs | 2 | 2024 | 280 | 0.270 |
Why?
|
| Inflammation | 2 | 2024 | 601 | 0.270 |
Why?
|
| Male | 19 | 2024 | 12870 | 0.270 |
Why?
|
| Patient Selection | 2 | 2017 | 143 | 0.270 |
Why?
|
| Trabeculectomy | 2 | 2016 | 13 | 0.260 |
Why?
|
| Cystadenocarcinoma, Serous | 2 | 2016 | 31 | 0.260 |
Why?
|
| Young Adult | 12 | 2021 | 2581 | 0.260 |
Why?
|
| Smoking Cessation | 3 | 2020 | 398 | 0.260 |
Why?
|
| Clinical Trials as Topic | 2 | 2017 | 205 | 0.250 |
Why?
|
| HEK293 Cells | 7 | 2020 | 172 | 0.250 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2018 | 444 | 0.250 |
Why?
|
| Electronic Nicotine Delivery Systems | 2 | 2020 | 194 | 0.250 |
Why?
|
| Liver Cirrhosis | 2 | 2024 | 67 | 0.250 |
Why?
|
| Glaucoma Drainage Implants | 2 | 2016 | 10 | 0.250 |
Why?
|
| Glaucoma | 2 | 2016 | 52 | 0.240 |
Why?
|
| Platinum Compounds | 3 | 2019 | 13 | 0.240 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2019 | 279 | 0.240 |
Why?
|
| Intraocular Pressure | 4 | 2022 | 61 | 0.230 |
Why?
|
| Oklahoma | 5 | 2021 | 973 | 0.210 |
Why?
|
| Smoking | 2 | 2019 | 465 | 0.210 |
Why?
|
| Tears | 2 | 2021 | 10 | 0.210 |
Why?
|
| Liver | 4 | 2019 | 415 | 0.200 |
Why?
|
| Disease-Free Survival | 6 | 2019 | 225 | 0.200 |
Why?
|
| Age Factors | 6 | 2021 | 716 | 0.190 |
Why?
|
| Neoplasm Metastasis | 2 | 2019 | 150 | 0.190 |
Why?
|
| Saliva | 2 | 2019 | 94 | 0.190 |
Why?
|
| Punctal Plugs | 1 | 2021 | 3 | 0.190 |
Why?
|
| Dry Eye Syndromes | 1 | 2021 | 5 | 0.190 |
Why?
|
| Pulmonary Embolism | 1 | 2022 | 126 | 0.190 |
Why?
|
| Cell Membrane | 2 | 2019 | 235 | 0.180 |
Why?
|
| Visual Acuity | 3 | 2016 | 106 | 0.180 |
Why?
|
| Pinocytosis | 1 | 2020 | 17 | 0.180 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2020 | 59 | 0.170 |
Why?
|
| Receptors, Melanocortin | 1 | 2019 | 6 | 0.170 |
Why?
|
| Integrin beta1 | 1 | 2019 | 15 | 0.170 |
Why?
|
| Integrin alpha3 | 1 | 2019 | 18 | 0.170 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2024 | 130 | 0.170 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2019 | 37 | 0.170 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2019 | 46 | 0.170 |
Why?
|
| Obesity | 2 | 2016 | 650 | 0.160 |
Why?
|
| Deoxycytidine | 1 | 2019 | 63 | 0.160 |
Why?
|
| Everolimus | 1 | 2019 | 16 | 0.160 |
Why?
|
| Gene Knockdown Techniques | 2 | 2019 | 131 | 0.160 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2019 | 44 | 0.160 |
Why?
|
| Incidence | 5 | 2022 | 545 | 0.160 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2019 | 12 | 0.160 |
Why?
|
| Apelin Receptors | 1 | 2019 | 11 | 0.160 |
Why?
|
| Prosthesis Implantation | 2 | 2016 | 26 | 0.160 |
Why?
|
| Diagnostic Errors | 1 | 2019 | 33 | 0.160 |
Why?
|
| Tobacco Smoking | 1 | 2019 | 38 | 0.160 |
Why?
|
| Hepatocytes | 2 | 2017 | 68 | 0.160 |
Why?
|
| Body Weight | 1 | 2019 | 246 | 0.160 |
Why?
|
| Keratoconus | 1 | 2018 | 8 | 0.160 |
Why?
|
| Registries | 2 | 2022 | 383 | 0.160 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2019 | 68 | 0.160 |
Why?
|
| Biomarkers | 2 | 2019 | 733 | 0.160 |
Why?
|
| Hysterectomy | 1 | 2019 | 80 | 0.160 |
Why?
|
| Sirolimus | 1 | 2019 | 68 | 0.150 |
Why?
|
| Guideline Adherence | 1 | 2019 | 91 | 0.150 |
Why?
|
| Claudin-1 | 1 | 2018 | 7 | 0.150 |
Why?
|
| Membrane Transport Modulators | 1 | 2018 | 2 | 0.150 |
Why?
|
| Patient Navigation | 1 | 2018 | 5 | 0.150 |
Why?
|
| Zonula Occludens-1 Protein | 1 | 2018 | 17 | 0.150 |
Why?
|
| Bevacizumab | 4 | 2022 | 93 | 0.150 |
Why?
|
| United States Indian Health Service | 1 | 2018 | 14 | 0.150 |
Why?
|
| Risk Factors | 6 | 2022 | 2011 | 0.150 |
Why?
|
| Autoimmune Diseases | 1 | 2019 | 162 | 0.150 |
Why?
|
| Biomarkers, Tumor | 2 | 2024 | 377 | 0.150 |
Why?
|
| Cigarette Smoking | 1 | 2019 | 77 | 0.150 |
Why?
|
| Glycoproteins | 1 | 2018 | 118 | 0.150 |
Why?
|
| Bortezomib | 1 | 2017 | 18 | 0.150 |
Why?
|
| Proteasome Inhibitors | 1 | 2017 | 24 | 0.150 |
Why?
|
| Tobacco Use Disorder | 1 | 2019 | 115 | 0.140 |
Why?
|
| Phthalazines | 1 | 2017 | 22 | 0.140 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2018 | 100 | 0.140 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2017 | 17 | 0.140 |
Why?
|
| Rifampin | 1 | 2017 | 7 | 0.140 |
Why?
|
| Dasatinib | 1 | 2017 | 16 | 0.140 |
Why?
|
| Signal Transduction | 6 | 2019 | 1344 | 0.140 |
Why?
|
| Piperazines | 1 | 2017 | 45 | 0.140 |
Why?
|
| Mitochondrial Membrane Transport Proteins | 1 | 2017 | 23 | 0.140 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2017 | 33 | 0.140 |
Why?
|
| Mice, Nude | 4 | 2019 | 313 | 0.140 |
Why?
|
| Calcium-Binding Proteins | 1 | 2017 | 60 | 0.140 |
Why?
|
| Adenocarcinoma | 1 | 2019 | 284 | 0.140 |
Why?
|
| Upper Extremity | 1 | 2016 | 27 | 0.140 |
Why?
|
| Patient Participation | 1 | 2017 | 52 | 0.140 |
Why?
|
| Glycolysis | 1 | 2017 | 82 | 0.140 |
Why?
|
| Vision, Low | 1 | 2016 | 4 | 0.140 |
Why?
|
| Spinal Puncture | 1 | 2016 | 11 | 0.140 |
Why?
|
| Intracranial Pressure | 1 | 2016 | 11 | 0.140 |
Why?
|
| Survival Rate | 4 | 2019 | 406 | 0.140 |
Why?
|
| Pseudotumor Cerebri | 1 | 2016 | 14 | 0.130 |
Why?
|
| Optic Nerve Diseases | 1 | 2016 | 16 | 0.130 |
Why?
|
| United States | 5 | 2022 | 2033 | 0.130 |
Why?
|
| Histone Acetyltransferases | 1 | 2016 | 15 | 0.130 |
Why?
|
| Drug Resistance, Multiple | 1 | 2016 | 20 | 0.130 |
Why?
|
| Tobacco Products | 1 | 2020 | 190 | 0.130 |
Why?
|
| Alkylating Agents | 1 | 2016 | 7 | 0.130 |
Why?
|
| Mitomycin | 1 | 2016 | 19 | 0.130 |
Why?
|
| Filtering Surgery | 1 | 2016 | 9 | 0.130 |
Why?
|
| Intensive Care Units | 1 | 2016 | 46 | 0.130 |
Why?
|
| Chloroquine | 1 | 2016 | 8 | 0.130 |
Why?
|
| Trabecular Meshwork | 1 | 2016 | 16 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2017 | 143 | 0.130 |
Why?
|
| Laser Therapy | 1 | 2016 | 30 | 0.130 |
Why?
|
| Animals | 9 | 2019 | 9963 | 0.130 |
Why?
|
| Decompression, Surgical | 1 | 2016 | 73 | 0.130 |
Why?
|
| Genital Neoplasms, Female | 1 | 2016 | 61 | 0.130 |
Why?
|
| RNAi Therapeutics | 1 | 2015 | 13 | 0.130 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2015 | 464 | 0.130 |
Why?
|
| Neoplasm Staging | 4 | 2018 | 456 | 0.130 |
Why?
|
| Pectins | 1 | 2015 | 7 | 0.130 |
Why?
|
| Mucositis | 1 | 2015 | 7 | 0.130 |
Why?
|
| RNA, Messenger | 1 | 2018 | 646 | 0.130 |
Why?
|
| Radiation-Protective Agents | 1 | 2015 | 22 | 0.130 |
Why?
|
| Athletic Injuries | 1 | 2016 | 116 | 0.120 |
Why?
|
| Gene Expression Regulation | 2 | 2016 | 623 | 0.120 |
Why?
|
| Radiation Injuries, Experimental | 1 | 2015 | 31 | 0.120 |
Why?
|
| Herpes Zoster Ophthalmicus | 1 | 2015 | 3 | 0.120 |
Why?
|
| Knowledge Bases | 1 | 2015 | 5 | 0.120 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2015 | 58 | 0.120 |
Why?
|
| Time Factors | 5 | 2021 | 1562 | 0.120 |
Why?
|
| Population Surveillance | 1 | 2015 | 85 | 0.120 |
Why?
|
| Cell Proliferation | 4 | 2019 | 771 | 0.120 |
Why?
|
| Genetic Therapy | 1 | 2015 | 116 | 0.120 |
Why?
|
| Glycated Hemoglobin A | 1 | 2015 | 64 | 0.120 |
Why?
|
| Stem Cells | 1 | 2015 | 113 | 0.120 |
Why?
|
| Corneal Dystrophies, Hereditary | 1 | 2014 | 4 | 0.120 |
Why?
|
| Corneal Ulcer | 1 | 2014 | 12 | 0.120 |
Why?
|
| Epithelium, Corneal | 1 | 2014 | 14 | 0.110 |
Why?
|
| Subcutaneous Fat | 1 | 2014 | 16 | 0.110 |
Why?
|
| Intra-Abdominal Fat | 1 | 2014 | 20 | 0.110 |
Why?
|
| Oculomotor Muscles | 1 | 2014 | 17 | 0.110 |
Why?
|
| Strabismus | 1 | 2014 | 19 | 0.110 |
Why?
|
| Ophthalmologic Surgical Procedures | 1 | 2014 | 23 | 0.110 |
Why?
|
| Research Design | 1 | 2015 | 174 | 0.110 |
Why?
|
| Granuloma, Plasma Cell | 1 | 2013 | 2 | 0.110 |
Why?
|
| Lymphatic Diseases | 1 | 2013 | 3 | 0.110 |
Why?
|
| Foreign-Body Reaction | 1 | 2013 | 3 | 0.110 |
Why?
|
| Wound Healing | 1 | 2014 | 113 | 0.110 |
Why?
|
| Hip Prosthesis | 1 | 2013 | 11 | 0.110 |
Why?
|
| Vasculitis | 1 | 2013 | 13 | 0.110 |
Why?
|
| Caregivers | 1 | 2015 | 110 | 0.110 |
Why?
|
| Treatment Outcome | 5 | 2019 | 2264 | 0.110 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2014 | 104 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2015 | 121 | 0.110 |
Why?
|
| Phosphorylation | 3 | 2019 | 560 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2014 | 131 | 0.110 |
Why?
|
| Metals | 1 | 2013 | 39 | 0.110 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2013 | 29 | 0.110 |
Why?
|
| Disease Progression | 3 | 2019 | 450 | 0.100 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2017 | 107 | 0.100 |
Why?
|
| Cisplatin | 3 | 2019 | 172 | 0.100 |
Why?
|
| Prospective Studies | 3 | 2022 | 1217 | 0.100 |
Why?
|
| Surveys and Questionnaires | 4 | 2019 | 918 | 0.100 |
Why?
|
| Postoperative Complications | 2 | 2014 | 604 | 0.100 |
Why?
|
| Cell Movement | 3 | 2019 | 353 | 0.100 |
Why?
|
| Mice | 5 | 2019 | 4408 | 0.100 |
Why?
|
| Cell Survival | 3 | 2018 | 394 | 0.090 |
Why?
|
| Paclitaxel | 3 | 2017 | 183 | 0.090 |
Why?
|
| Proportional Hazards Models | 3 | 2014 | 213 | 0.080 |
Why?
|
| Disease Models, Animal | 3 | 2019 | 1394 | 0.080 |
Why?
|
| Age Distribution | 2 | 2021 | 70 | 0.080 |
Why?
|
| STAT3 Transcription Factor | 2 | 2019 | 85 | 0.080 |
Why?
|
| Biological Transport | 2 | 2019 | 111 | 0.080 |
Why?
|
| Prevalence | 2 | 2019 | 472 | 0.070 |
Why?
|
| Estradiol | 2 | 2019 | 174 | 0.070 |
Why?
|
| Neoplasm Grading | 2 | 2018 | 104 | 0.070 |
Why?
|
| Cell Line | 2 | 2019 | 673 | 0.070 |
Why?
|
| Taxoids | 2 | 2017 | 36 | 0.070 |
Why?
|
| Immunohistochemistry | 2 | 2018 | 453 | 0.070 |
Why?
|
| Neutropenia | 2 | 2017 | 35 | 0.070 |
Why?
|
| Biological Transport, Active | 2 | 2017 | 17 | 0.070 |
Why?
|
| Neoadjuvant Therapy | 2 | 2017 | 67 | 0.070 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2018 | 251 | 0.070 |
Why?
|
| Cohort Studies | 2 | 2020 | 858 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2020 | 390 | 0.060 |
Why?
|
| Prognosis | 2 | 2021 | 759 | 0.060 |
Why?
|
| Epithelial Cells | 2 | 2017 | 240 | 0.060 |
Why?
|
| Protein Binding | 2 | 2017 | 632 | 0.060 |
Why?
|
| Apoptosis | 2 | 2018 | 739 | 0.060 |
Why?
|
| Phenotype | 2 | 2017 | 665 | 0.060 |
Why?
|
| Carcinogenesis | 1 | 2024 | 76 | 0.060 |
Why?
|
| Liver Diseases | 1 | 2024 | 51 | 0.060 |
Why?
|
| Cells, Cultured | 2 | 2017 | 970 | 0.060 |
Why?
|
| Multivariate Analysis | 2 | 2014 | 298 | 0.050 |
Why?
|
| Body Mass Index | 2 | 2016 | 386 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2024 | 263 | 0.050 |
Why?
|
| Gonioscopy | 1 | 2022 | 7 | 0.050 |
Why?
|
| Endometrium | 1 | 2022 | 38 | 0.050 |
Why?
|
| Cervix Uteri | 1 | 2022 | 63 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2014 | 980 | 0.050 |
Why?
|
| Indoles | 1 | 2022 | 98 | 0.050 |
Why?
|
| Povidone-Iodine | 1 | 2021 | 8 | 0.050 |
Why?
|
| Intravitreal Injections | 1 | 2021 | 33 | 0.050 |
Why?
|
| Eye | 1 | 2021 | 35 | 0.050 |
Why?
|
| Infant | 2 | 2015 | 957 | 0.050 |
Why?
|
| Child, Preschool | 2 | 2015 | 1091 | 0.050 |
Why?
|
| Organic Anion Transporters, Sodium-Independent | 1 | 2020 | 4 | 0.040 |
Why?
|
| Protein Domains | 1 | 2020 | 48 | 0.040 |
Why?
|
| Gene Silencing | 1 | 2020 | 63 | 0.040 |
Why?
|
| Enzyme Activation | 1 | 2020 | 262 | 0.040 |
Why?
|
| Equilibrative Nucleoside Transporter 1 | 1 | 2019 | 15 | 0.040 |
Why?
|
| Antigen-Presenting Cells | 1 | 2019 | 31 | 0.040 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2019 | 33 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2019 | 52 | 0.040 |
Why?
|
| Immunomodulation | 1 | 2019 | 19 | 0.040 |
Why?
|
| Neoplasm Transplantation | 1 | 2019 | 88 | 0.040 |
Why?
|
| Flavoring Agents | 1 | 2019 | 15 | 0.040 |
Why?
|
| Spheroids, Cellular | 1 | 2019 | 52 | 0.040 |
Why?
|
| Uveitis | 1 | 2019 | 23 | 0.040 |
Why?
|
| Biotinylation | 1 | 2019 | 19 | 0.040 |
Why?
|
| Histocytochemistry | 1 | 2019 | 20 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 72 | 0.040 |
Why?
|
| Nitrobenzoates | 1 | 2019 | 7 | 0.040 |
Why?
|
| Pyrans | 1 | 2019 | 8 | 0.040 |
Why?
|
| Cotinine | 1 | 2019 | 45 | 0.040 |
Why?
|
| Surface Properties | 1 | 2019 | 132 | 0.040 |
Why?
|
| Salivary Proteins and Peptides | 1 | 2018 | 6 | 0.040 |
Why?
|
| Cell Adhesion | 1 | 2019 | 133 | 0.040 |
Why?
|
| HeLa Cells | 1 | 2019 | 206 | 0.040 |
Why?
|
| Smokers | 1 | 2020 | 124 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2018 | 94 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2021 | 587 | 0.040 |
Why?
|
| Caspases | 1 | 2018 | 43 | 0.040 |
Why?
|
| Inflammation Mediators | 1 | 2019 | 152 | 0.040 |
Why?
|
| ROC Curve | 1 | 2018 | 139 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 1 | 2019 | 93 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 124 | 0.040 |
Why?
|
| Autoimmunity | 1 | 2019 | 153 | 0.040 |
Why?
|
| Autoantigens | 1 | 2019 | 212 | 0.040 |
Why?
|
| Heterografts | 1 | 2018 | 62 | 0.040 |
Why?
|
| Child | 2 | 2015 | 2147 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 253 | 0.040 |
Why?
|
| Membrane Transport Proteins | 1 | 2018 | 65 | 0.040 |
Why?
|
| Extracellular Matrix | 1 | 2019 | 111 | 0.040 |
Why?
|
| Intravital Microscopy | 1 | 2018 | 10 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2019 | 147 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2017 | 23 | 0.040 |
Why?
|
| Patient Compliance | 1 | 2018 | 75 | 0.040 |
Why?
|
| Ubiquitination | 1 | 2017 | 32 | 0.040 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2017 | 26 | 0.040 |
Why?
|
| Quinolines | 1 | 2017 | 25 | 0.040 |
Why?
|
| Microscopy, Confocal | 1 | 2018 | 110 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2018 | 117 | 0.040 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2018 | 110 | 0.040 |
Why?
|
| Substrate Specificity | 1 | 2017 | 149 | 0.040 |
Why?
|
| Pyruvate Dehydrogenase Complex | 1 | 2017 | 19 | 0.040 |
Why?
|
| Infusions, Parenteral | 1 | 2017 | 34 | 0.040 |
Why?
|
| Oxidative Phosphorylation | 1 | 2017 | 26 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase 7 | 1 | 2017 | 5 | 0.040 |
Why?
|
| Cytokines | 1 | 2019 | 438 | 0.040 |
Why?
|
| Microarray Analysis | 1 | 2017 | 59 | 0.040 |
Why?
|
| Casein Kinase II | 1 | 2017 | 17 | 0.040 |
Why?
|
| Contusions | 1 | 2016 | 3 | 0.040 |
Why?
|
| Tendon Injuries | 1 | 2016 | 3 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2018 | 324 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2017 | 30 | 0.030 |
Why?
|
| Lacerations | 1 | 2016 | 7 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2018 | 503 | 0.030 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2017 | 17 | 0.030 |
Why?
|
| Proteolysis | 1 | 2017 | 55 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2016 | 76 | 0.030 |
Why?
|
| Eye Proteins | 1 | 2018 | 197 | 0.030 |
Why?
|
| Professional Competence | 1 | 2016 | 36 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2019 | 537 | 0.030 |
Why?
|
| Visual Fields | 1 | 2016 | 31 | 0.030 |
Why?
|
| Lysine Acetyltransferase 5 | 1 | 2016 | 4 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2016 | 68 | 0.030 |
Why?
|
| Optic Nerve | 1 | 2016 | 28 | 0.030 |
Why?
|
| Acetylation | 1 | 2016 | 36 | 0.030 |
Why?
|
| Organoplatinum Compounds | 1 | 2016 | 23 | 0.030 |
Why?
|
| Tonometry, Ocular | 1 | 2016 | 8 | 0.030 |
Why?
|
| Syndrome | 1 | 2016 | 78 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2018 | 400 | 0.030 |
Why?
|
| Monensin | 1 | 2016 | 4 | 0.030 |
Why?
|
| Calcium | 1 | 2017 | 231 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2016 | 74 | 0.030 |
Why?
|
| Macrolides | 1 | 2016 | 18 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 910 | 0.030 |
Why?
|
| Histones | 1 | 2016 | 90 | 0.030 |
Why?
|
| Antimalarials | 1 | 2016 | 22 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 357 | 0.030 |
Why?
|
| Reoperation | 1 | 2016 | 144 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2015 | 46 | 0.030 |
Why?
|
| Chronic Pain | 1 | 2016 | 59 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 439 | 0.030 |
Why?
|
| Models, Biological | 1 | 2018 | 446 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2016 | 122 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 58 | 0.030 |
Why?
|
| Gastric Mucosa | 1 | 2015 | 35 | 0.030 |
Why?
|
| Thrombocytopenia | 1 | 2017 | 113 | 0.030 |
Why?
|
| Chickenpox Vaccine | 1 | 2015 | 3 | 0.030 |
Why?
|
| Antifungal Agents | 1 | 2016 | 58 | 0.030 |
Why?
|
| Whole-Body Irradiation | 1 | 2015 | 38 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2016 | 197 | 0.030 |
Why?
|
| RNA Interference | 1 | 2015 | 135 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2015 | 108 | 0.030 |
Why?
|
| Age of Onset | 1 | 2015 | 68 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 288 | 0.030 |
Why?
|
| Sex Factors | 1 | 2016 | 446 | 0.030 |
Why?
|
| Transfection | 1 | 2015 | 313 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2016 | 282 | 0.030 |
Why?
|
| Kinetics | 1 | 2016 | 538 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2015 | 276 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2015 | 240 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2016 | 330 | 0.030 |
Why?
|
| Neoplastic Stem Cells | 1 | 2015 | 138 | 0.030 |
Why?
|
| Vaccination | 1 | 2015 | 167 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2014 | 67 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2014 | 76 | 0.030 |
Why?
|
| Carboplatin | 1 | 2014 | 106 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2015 | 213 | 0.030 |
Why?
|
| Prosthesis Failure | 1 | 2013 | 21 | 0.030 |
Why?
|
| Adiposity | 1 | 2014 | 87 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2015 | 300 | 0.030 |
Why?
|
| Mutation | 1 | 2017 | 817 | 0.030 |
Why?
|
| Prosthesis Design | 1 | 2013 | 82 | 0.030 |
Why?
|
| Overweight | 1 | 2014 | 110 | 0.030 |
Why?
|
| Recurrence | 1 | 2014 | 316 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2014 | 176 | 0.030 |
Why?
|
| Quality of Life | 1 | 2016 | 464 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2015 | 509 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 1476 | 0.020 |
Why?
|